ClinicalTrials.gg
CompletedNCT00927082Updated Mar 9, 2016Results posted

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

A Phase 4 interventional study of peginterferon alfa-2a [Pegasys] in Hepatitis B, Chronic, sponsored by Hoffmann-La Roche. Completed at 31 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-09.

Sponsored by Hoffmann-La Roche · Phase 4 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
383
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic — 1 open to participants now, 1 under way, none of them phase 3. peginterferon alfa-2a · Hepatitis B, Chronic.

Enrollment
4th of 59
383 · median 114
Started
2009
with 5 others
Phase 4
29 of 59
none open now
Registered
15th of 59
by date
Lead sponsor
22 of 59
Hoffmann-La Roche

Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, this one is the 4th largest by enrollment, is one of 6 that started in 2009, is one of 29 in phase 4, and was the 15th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

1 of the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

This study is a long-term post-treatment follow-up to study WV19432, which evaluated the efficacy and safety of PEGASYS in patients with HBeAg positive chronic hepatitis B (CHB).Patients who received treatment with PEGASYS, and completed follow-up, are eligible to enter this post-treatment follow-up study. The anticipated time on study was 5 years, and the target sample size is 100-500 individuals.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • for Study WV19432
  • Patients who have completed treatment and follow-up on study WV19432

Exclusion criteria

Exclusion Criteria:

  • As for Study WV19432
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
383 participants (actual)

Study arms

  • Experimental
    PEG-IFN 90mcg 24 Wks

    Participants received Pegasys (Pegylated interferon alfa-2a \[PEG-IFN\]) 90 micrograms (mcg) subcutaneously (SC) once a week for 24 weeks in Study WV19432 and entered follow-up (FU) Study MV22430.

    Drug: peginterferon alfa-2a [Pegasys]

  • Experimental
    PEG-IFN 180mcg 24 Wks

    Participants received PEG-IFN 180 mcg SC once a week for 24 weeks in Study WV19432 and entered FU Study MV22430.

    Drug: peginterferon alfa-2a [Pegasys]

  • Experimental
    PEG-IFN 90mcg 48 Wks

    Participants received PEG-IFN 90 mcg SC once a week for 48 weeks in Study WV19432 and entered FU Study MV22430.

    Drug: peginterferon alfa-2a [Pegasys]

  • Experimental
    PEG-IFN 180mcg 48 Wks

    Participants received PEG-IFN 180 mcg SC once a week for 48 weeks in Study WV19432 and entered FU Study MV22430.

    Drug: peginterferon alfa-2a [Pegasys]

Interventions

  • 90 or 180 micrograms/week sc for 24 or 48 weeks in original study (WV19432). No study treatment in long-term post-treatment follow-up study (MV22430)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Hepatitis B Envelope Antigen (HBeAg) Seroconversion.

    HBeAg seroconversion was defined as the absence of HBeAg (a negative result for HBeAg) and the presence of anti-HBe (a positive result for anti-HBe). Missing values were counted as non-response.

    Time frame: Annually, for up to 5 years

  2. Percentage of Participants With HBsAg Loss

    HBsAg loss is defined as the absence of HBsAg (i.e. a negative result for HBsAg). Missing values were counted as non-response.

    Time frame: Annually, for up to 5 years

Secondary outcomes

  1. Percentage of Participants With HBeAg Loss.

    HBeAg loss is defined as the absence of HBeAg (i.e. a negative result for HBeAg). Missing values were counted as non-response.

    Time frame: Annually, for up to 5 years

  2. Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Seroconversion.

    HBsAg seroconversion was defined as the absence of HBsAg (a negative result for HBsAg) and the presence of anti-HBs (a positive result for anti-HBs). Missing values were counted as non-response.

    Time frame: Annually, for up to 5 years

  3. Percentage of Participants With Presence of Anti-Hepatitis B Envelope Antigen (HBe).

    The presence of anti-HBe is defined as antibody produced against e antigen in HBeAg. Seroconversion from e antigen to e antibody (anti-HBe) is a predictor of long-term clearance of hepatitis B virus (HBV) in participants undergoing antiviral therapy and indicates lower levels of HBV, and therefore lower infectivity. Missing values were counted as non-response.

    Time frame: Annually, for up to 5 years

  4. Percentage of Participants With Presence of Anti-HBs

    The presence of anti-HBs is defined as antibody produced against HBsAg.It is generally interpreted as indicating recovery and immunity from HBV infection. Missing values were counted as non-response.

    Time frame: Annually, for up to 5 years

  5. Percentage of Participants With Normalised Alanine Transaminase (ALT)

    Alanine Transaminase is an enzyme found mainly in liver and is measured to check if the liver is damaged or diseased. In case of liver damage or disease, the liver releases ALT into the blood stream and the ALT levels increase. Missing values were counted as non-response.

    Time frame: Annually, for up to 5 years

  6. Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) Suppression < 20,000 International Unit/Milliliter (IU/mL).

    The percentage of participants with HBV-DNA suppression \< 20,000 IU/mL. HBV DNA is the genetic material that carries the blueprint of the virus. The measure of HBV DNA in blood indicates how rapidly the virus is replicating in liver. Missing values were counted as non-response.

    Time frame: Annually, for up to 5 years

  7. Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) Suppression < 2,000 International Unit/Milliliter (IU/mL)

    The percentage of participants with HBV-DNA suppression \< 2,000 IU/mL. HBV DNA is the genetic material that carries the blueprint of the virus. The measure of HBV DNA in blood indicates how rapidly the virus is replicating in liver. Missing values were counted as non-response.

    Time frame: Annually, for up to 5 years

  8. Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) Suppression < 80 International Unit/Milliliter (IU/mL)

    The percentage of participants with HBV-DNA suppression \< 80 IU/mL. HBV DNA is the genetic material that carries the blueprint of the virus. The measure of HBV DNA in blood indicates how rapidly the virus is replicating in liver. Missing values were counted as non-response.

    Time frame: Annually, for up to 5 years

  9. Quantitative HBsAg

    Quantitative HBsAg assay is a diagnostic test for assessing the amount of the HBsAg in chronic Hepatitis B participants. Missing values were counted as non-response.

    Time frame: Annually, for up to 5 years

  10. Number of Participants Who Received Treatment With Antiviral, Immunomodulatory, Anti-inflammatory or Herbal/Botanical/Other Treatments for Chronic Hepatitis B

    Participants who required additional treatments specifically to treat CHB, associated laboratory test abnormalities and associated symptoms in this long-term observation in the study were reported. Receipt of such treatment did not require participant withdrawal from further participation.

    Time frame: Up to 5-year FU period

  11. Number of Participants With Clinically Significant Events Related to Chronic Hepatitis B (CHB)

    Clinically significant events were defined as one or more of the following: Hepatocellular carcinoma, hepatic decompensation, CHB-related death, hepatic transplant, marked elevation of serum ALT of \>10 x upper limit of normal (ULN).

    Time frame: Up to 5-year FU period

  12. Number of Participants With Marked Laboratory Abnormalities

    Marked abnormality of laboratory parameters is defined as the value which is outside the defined reference range of that respective parameter. Roche's following reference ranges for laboratory test parameters were used for the analysis: Hemoglobin (reference range: 110-200 grams/liter\[g/L\]), White blood cells (WBC) (3.0-18.0 \^10\^9/L), Platelets (100-550 \^10\^9/L), Neutrophils (1.50-9.25 \^10\^9/L), Prothrombin time (PT) Normal ratio (n.d.-2.00), Alkaline phosphatase (0-220 units/liter \[U/L\]), Alanine aminotransferase (0-110 U/L), Aspartate transaminase (0-80 U/L), Total bilirubin (0-34 micromole/liter \[umol/L\]), Gamma-glutamyl transpeptidase (GGT) (0-190 U/L), Blood urea nitrogen (BUN) (0.0-14.3 millimole/liter \[mmol/L\]), Creatinine (0-154 umol/L), Total Protein (55-87 g/L), Albumin (30.0-n.d. g/L), Potassium (2.9-5.8 mmol/L), Sodium (130-150 mmol/L), Calcium (2.00-2.90 mmol/L), Uric acid (0-600 umol/L). It includes marked abnormalities observed during Study WV19432 and FU study MV22430

    Time frame: Up to 5-year FU period

07

Results

Posted Mar 9, 2016
Limitations and caveats
Of the responders at FU Year 5, the proportion of patients who were receiving additional anti-HBV treatment after FU Week 24 varied between groups. The frequency of missing values (counted as non-response) was unevenly distributed between groups.

Participant flow

The study was conducted from 10 April 2009 to 05 November 2014. A total of 383 participants were recruited from 31 centers across 9 countries (Australia, New Zealand, China, Taiwan, Singapore, Korea, Thailand, Brazil, and Russia).

Participant flow — Overall Study
MilestonePEG-IFN 90mcg 24 WksPEG-IFN 180mcg 24 WksPEG-IFN 90mcg 48 WksPEG-IFN 180mcg 48 Wks
Started918710897
Completed79778678
Not completed12102219
Withdrew: Lost to follow-up981216
Withdrew: Withdrawal by subject3272
Withdrew: Death0010
Withdrew: Screen fail,participant migrated,unknown0021

Outcome measures

PrimaryPercentage of Participants With Hepatitis B Envelope Antigen (HBeAg) Seroconversion.

HBeAg seroconversion was defined as the absence of HBeAg (a negative result for HBeAg) and the presence of anti-HBe (a positive result for anti-HBe). Missing values were counted as non-response.

Time frame:
Annually, for up to 5 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Hepatitis B Envelope Antigen (HBeAg) Seroconversion.
Percentage of participantsPEG-IFN 90mcg 24 WksPEG-IFN 180mcg 24 WksPEG-IFN 90mcg 48 WksPEG-IFN 180mcg 48 Wks
End of Treatment (EOT)9.7 (4.5 to 17.6)14.6 (8.0 to 23.7)19.8 (12.7 to 28.7)31.6 (22.4 to 41.9)
FU Year 120.4 (12.8 to 30.1)31.5 (22.0 to 42.2)27.4 (19.1 to 36.9)35.8 (26.2 to 46.3)
FU Year 226.9 (18.2 to 37.1)37.1 (27.1 to 48.0)30.2 (21.7 to 39.9)47.4 (37.0 to 57.9)
FU Year 338.7 (28.8 to 49.4)40.4 (30.2 to 51.4)34.0 (25.0 to 43.8)52.6 (42.1 to 63.0)
FU Year 437.6 (27.8 to 48.3)44.9 (34.4 to 55.9)41.5 (32.0 to 51.5)49.5 (39.1 to 59.9)
FU Year 541.9 (31.8 to 52.6)44.9 (34.4 to 55.9)40.6 (31.1 to 50.5)48.4 (38.0 to 58.9)
SecondaryPercentage of Participants With HBeAg Loss.

HBeAg loss is defined as the absence of HBeAg (i.e. a negative result for HBeAg). Missing values were counted as non-response.

Time frame:
Annually, for up to 5 years
Reported as:
Number · Percentage of participants
Percentage of Participants With HBeAg Loss.
Percentage of participantsPEG-IFN 90mcg 24 WksPEG-IFN 180mcg 24 WksPEG-IFN 90mcg 48 WksPEG-IFN 180mcg 48 Wks
EOT9.7 (4.5 to 17.6)14.6 (8.0 to 23.7)19.8 (12.7 to 28.7)33.7 (24.3 to 44.1)
FU Year 123.7 (15.5 to 33.6)31.5 (22.0 to 42.2)30.2 (21.7 to 39.9)36.8 (27.2 to 47.4)
FU Year 230.1 (21.0 to 40.5)38.2 (28.1 to 49.1)33.0 (24.2 to 42.8)48.4 (38.0 to 58.9)
FU Year 341.9 (31.8 to 52.6)46.1 (35.4 to 57.0)38.7 (29.4 to 48.6)53.7 (43.2 to 64.0)
FU Year 446.2 (35.8 to 56.9)49.4 (38.7 to 60.2)49.1 (39.2 to 59.0)53.7 (43.2 to 64.0)
FU Year 550.5 (40.0 to 61.1)49.4 (38.7 to 60.2)50.0 (40.1 to 59.9)51.6 (41.1 to 62.0)
SecondaryPercentage of Participants With Hepatitis B Surface Antigen (HBsAg) Seroconversion.

HBsAg seroconversion was defined as the absence of HBsAg (a negative result for HBsAg) and the presence of anti-HBs (a positive result for anti-HBs). Missing values were counted as non-response.

Time frame:
Annually, for up to 5 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Seroconversion.
Percentage of participantsPEG-IFN 90mcg 24 WksPEG-IFN 180mcg 24 WksPEG-IFN 90mcg 48 WksPEG-IFN 180mcg 48 Wks
EOT0.0 (0.0 to 3.9)1.1 (0.0 to 6.1)1.9 (0.2 to 6.6)3.2 (0.7 to 9.0)
FU Year 11.1 (0.0 to 5.8)0.0 (0.0 to 4.1)0.9 (0.0 to 5.1)1.1 (0.0 to 5.7)
FU Year 22.2 (0.3 to 7.6)0.0 (0.0 to 4.1)0.9 (0.0 to 5.1)3.2 (0.7 to 9.0)
FU Year 33.2 (0.7 to 9.1)0.0 (0.0 to 4.1)0.9 (0.0 to 5.1)3.2 (0.7 to 9.0)
FU Year 43.2 (0.7 to 9.1)0.0 (0.0 to 4.1)0.9 (0.0 to 5.1)2.1 (0.3 to 7.4)
FU Year 53.2 (0.7 to 9.1)0.0 (0.0 to 4.1)1.9 (0.2 to 6.6)2.1 (0.3 to 7.4)
SecondaryPercentage of Participants With Presence of Anti-Hepatitis B Envelope Antigen (HBe).

The presence of anti-HBe is defined as antibody produced against e antigen in HBeAg. Seroconversion from e antigen to e antibody (anti-HBe) is a predictor of long-term clearance of hepatitis B virus (HBV) in participants undergoing antiviral therapy and indicates lower levels of HBV, and therefore lower infectivity. Missing values were counted as non-response.

Time frame:
Annually, for up to 5 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Presence of Anti-Hepatitis B Envelope Antigen (HBe).
Percentage of participantsPEG-IFN 90mcg 24 WksPEG-IFN 180mcg 24 WksPEG-IFN 90mcg 48 WksPEG-IFN 180mcg 48 Wks
EOT23.7 (15.5 to 33.6)27.0 (18.1 to 37.4)29.2 (20.8 to 38.9)40.0 (30.1 to 50.6)
FU Year 128.0 (19.1 to 38.2)42.7 (32.3 to 53.6)28.3 (20.0 to 37.9)38.9 (29.1 to 49.5)
FU Year 231.2 (22.0 to 41.6)40.4 (30.2 to 51.4)33.0 (24.2 to 42.8)50.5 (40.1 to 60.9)
FU Year 341.9 (31.8 to 52.6)42.7 (32.3 to 53.6)36.8 (27.6 to 46.7)55.8 (45.2 to 66.0)
FU Year 437.6 (27.8 to 48.3)44.9 (34.4 to 55.9)41.5 (32.0 to 51.5)52.6 (42.1 to 63.0)
FU Year 543.0 (32.8 to 53.7)48.3 (37.6 to 59.2)42.5 (32.9 to 52.4)50.5 (40.1 to 60.9)
SecondaryPercentage of Participants With Presence of Anti-HBs

The presence of anti-HBs is defined as antibody produced against HBsAg.It is generally interpreted as indicating recovery and immunity from HBV infection. Missing values were counted as non-response.

Time frame:
Annually, for up to 5 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Presence of Anti-HBs
Percentage of participantsPEG-IFN 90mcg 24 WksPEG-IFN 180mcg 24 WksPEG-IFN 90mcg 48 WksPEG-IFN 180mcg 48 Wks
EOT4.3 (1.2 to 10.6)2.2 (0.3 to 7.9)11.3 (6.0 to 18.9)9.5 (4.4 to 17.2)
FU Year 16.5 (2.4 to 13.5)3.4 (0.7 to 9.5)7.5 (3.3 to 14.3)7.4 (3.0 to 14.6)
FU Year 25.4 (1.8 to 12.1)10.1 (4.7 to 18.3)6.6 (2.7 to 13.1)6.3 (2.4 to 13.2)
FU Year 34.3 (1.2 to 10.6)4.5 (1.2 to 11.1)7.5 (3.3 to 14.3)5.3 (1.7 to 11.9)
FU Year 44.3 (1.2 to 10.6)3.4 (0.7 to 9.5)4.7 (1.5 to 10.7)5.3 (1.7 to 11.9)
FU Year 53.2 (0.7 to 9.1)4.5 (1.2 to 11.1)5.7 (2.1 to 11.9)5.3 (1.7 to 11.9)
SecondaryPercentage of Participants With Normalised Alanine Transaminase (ALT)

Alanine Transaminase is an enzyme found mainly in liver and is measured to check if the liver is damaged or diseased. In case of liver damage or disease, the liver releases ALT into the blood stream and the ALT levels increase. Missing values were counted as non-response.

Time frame:
Annually, for up to 5 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Normalised Alanine Transaminase (ALT)
Percentage of participantsPEG-IFN 90mcg 24 WksPEG-IFN 180mcg 24 WksPEG-IFN 90mcg 48 WksPEG-IFN 180mcg 48 Wks
EOT28.0 (19.1 to 38.2)27.0 (18.1 to 37.4)38.7 (29.4 to 48.6)49.5 (39.1 to 59.9)
FU Year 145.2 (34.8 to 55.8)44.9 (34.4 to 55.9)49.1 (39.2 to 59.0)50.5 (40.1 to 60.9)
FU Year 258.1 (47.4 to 68.2)60.7 (49.7 to 70.9)55.7 (45.7 to 65.3)65.3 (54.8 to 74.7)
FU Year 366.7 (56.1 to 76.1)70.8 (60.2 to 79.9)54.7 (44.8 to 64.4)66.3 (55.9 to 75.7)
FU Year 467.7 (57.3 to 77.1)64.0 (53.2 to 73.9)62.3 (52.3 to 71.5)63.2 (52.6 to 72.8)
FU Year 569.9 (59.5 to 79.0)67.4 (56.7 to 77.0)56.6 (46.6 to 66.2)63.2 (52.6 to 72.8)
PrimaryPercentage of Participants With HBsAg Loss

HBsAg loss is defined as the absence of HBsAg (i.e. a negative result for HBsAg). Missing values were counted as non-response.

Time frame:
Annually, for up to 5 years
Reported as:
Number · Percentage
Percentage of Participants With HBsAg Loss
PercentagePEG-IFN 90mcg 24 WksPEG-IFN 180mcg 24 WksPEG-IFN 90mcg 48 WksPEG-IFN 180mcg 48 Wks
EOT0.0 (0.0 to 3.9)1.1 (0.0 to 6.1)1.9 (0.2 to 6.6)3.2 (0.7 to 9.0)
FU Year 11.1 (0.0 to 5.8)0.0 (0.0 to 4.1)0.9 (0.0 to 5.1)1.1 (0.0 to 5.7)
FU Year 22.2 (0.3 to 7.6)0.0 (0.0 to 4.1)1.9 (0.2 to 6.6)3.2 (0.7 to 9.0)
FU Year 33.2 (0.7 to 9.1)0.0 (0.0 to 4.1)1.9 (0.2 to 6.6)3.2 (0.7 to 9.0)
FU Year 43.2 (0.7 to 9.1)0.0 (0.0 to 4.1)2.8 (0.6 to 8.0)2.1 (0.3 to 7.4)
FU Year 53.2 (0.7 to 9.1)0.0 (0.0 to 4.1)2.8 (0.6 to 8.0)2.1 (0.3 to 7.4)
SecondaryPercentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) Suppression < 20,000 International Unit/Milliliter (IU/mL).

The percentage of participants with HBV-DNA suppression \< 20,000 IU/mL. HBV DNA is the genetic material that carries the blueprint of the virus. The measure of HBV DNA in blood indicates how rapidly the virus is replicating in liver. Missing values were counted as non-response.

Time frame:
Annually, for up to 5 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) Suppression < 20,000 International Unit/Milliliter (IU/mL).
Percentage of participantsPEG-IFN 90mcg 24 WksPEG-IFN 180mcg 24 WksPEG-IFN 90mcg 48 WksPEG-IFN 180mcg 48 Wks
EOT22.6 (14.6 to 32.4)33.7 (24.0 to 44.5)34.0 (25.0 to 43.8)50.5 (40.1 to 60.9)
FU Year 133.3 (23.9 to 43.9)31.5 (22.0 to 42.2)45.3 (35.6 to 55.2)40.0 (30.1 to 50.6)
FU Year 257.0 (46.3 to 67.2)50.6 (39.8 to 61.3)58.5 (48.5 to 68.0)54.7 (44.2 to 65.0)
FU Year 367.7 (57.3 to 77.1)61.8 (50.9 to 71.9)61.3 (51.4 to 70.6)64.2 (53.7 to 73.8)
FU Year 469.9 (59.5 to 79.0)68.5 (57.8 to 78.0)68.9 (59.1 to 77.5)64.2 (53.7 to 73.8)
FU Year 567.7 (57.3 to 77.1)70.8 (60.2 to 79.9)67.0 (57.2 to 75.8)63.2 (52.6 to 72.8)
SecondaryPercentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) Suppression < 2,000 International Unit/Milliliter (IU/mL)

The percentage of participants with HBV-DNA suppression \< 2,000 IU/mL. HBV DNA is the genetic material that carries the blueprint of the virus. The measure of HBV DNA in blood indicates how rapidly the virus is replicating in liver. Missing values were counted as non-response.

Time frame:
Annually, for up to 5 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) Suppression < 2,000 International Unit/Milliliter (IU/mL)
Percentage of participantsPEG-IFN 90mcg 24 WksPEG-IFN 180mcg 24 WksPEG-IFN 90mcg 48 WksPEG-IFN 180mcg 48 Wks
EOT15.1 (8.5 to 24.0)21.3 (13.4 to 31.3)27.4 (19.1 to 36.9)45.3 (35.0 to 55.8)
FU Year 120.4 (12.8 to 30.1)23.6 (15.2 to 33.8)39.6 (30.3 to 49.6)31.6 (22.4 to 41.9)
FU Year 245.2 (34.8 to 55.8)39.3 (29.1 to 50.3)50.0 (40.1 to 59.9)45.3 (35.0 to 55.8)
FU Year 352.7 (42.1 to 63.1)52.8 (41.9 to 63.5)52.8 (42.9 to 62.6)52.6 (42.1 to 63.0)
FU Year 459.1 (48.5 to 69.2)56.2 (45.3 to 66.7)63.2 (53.3 to 72.4)54.7 (44.2 to 65.0)
FU Year 559.1 (48.5 to 69.2)61.8 (50.9 to 71.9)60.4 (50.4 to 69.7)57.9 (47.3 to 68.0)
SecondaryPercentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) Suppression < 80 International Unit/Milliliter (IU/mL)

The percentage of participants with HBV-DNA suppression \< 80 IU/mL. HBV DNA is the genetic material that carries the blueprint of the virus. The measure of HBV DNA in blood indicates how rapidly the virus is replicating in liver. Missing values were counted as non-response.

Time frame:
Annually, for up to 5 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) Suppression < 80 International Unit/Milliliter (IU/mL)
Percentage of participantsPEG-IFN 90mcg 24 WksPEG-IFN 180mcg 24 WksPEG-IFN 90mcg 48 WksPEG-IFN 180mcg 48 Wks
EOT5.4 (1.8 to 12.1)12.4 (6.3 to 21.0)16.0 (9.6 to 24.4)32.6 (23.4 to 43.0)
FU Year 112.9 (6.8 to 21.5)7.9 (3.2 to 15.5)17.9 (11.2 to 26.6)14.7 (8.3 to 23.5)
FU Year 228.0 (19.1 to 38.2)23.6 (15.2 to 33.8)36.8 (27.6 to 46.7)29.5 (20.6 to 39.7)
FU Year 339.8 (29.8 to 50.5)30.3 (21.0 to 41.0)34.9 (25.9 to 44.8)38.9 (29.1 to 49.5)
FU Year 447.3 (36.9 to 57.9)38.2 (28.1 to 49.1)46.2 (36.5 to 56.2)40.0 (30.1 to 50.6)
FU Year 539.8 (29.8 to 50.5)40.4 (30.2 to 51.4)42.5 (32.9 to 52.4)38.9 (29.1 to 49.5)
SecondaryQuantitative HBsAg

Quantitative HBsAg assay is a diagnostic test for assessing the amount of the HBsAg in chronic Hepatitis B participants. Missing values were counted as non-response.

Time frame:
Annually, for up to 5 years
Reported as:
Mean · log10 IU/mL
Quantitative HBsAg
log10 IU/mLPEG-IFN 90mcg 24 WksPEG-IFN 180mcg 24 WksPEG-IFN 90mcg 48 WksPEG-IFN 180mcg 48 Wks
EOT (n= 89, 86, 102, 91)3.541 ± 0.95233.371 ± 1.15703.322 ± 1.08752.949 ± 1.3170
FU Year 1 (n= 87, 85, 93, 86)3.495 ± 0.93143.484 ± 0.81023.379 ± 0.90763.453 ± 0.9282
FU Year 2 (n= 86, 86, 96, 90)3.478 ± 0.92633.441 ± 0.76823.381 ± 0.88983.318 ± 1.0139
FU Year 3 (n= 83, 82, 91, 85)3.479 ± 0.90083.393 ± 0.70953.339 ± 0.88703.178 ± 1.0561
FU Year 4 (n= 81, 79, 89, 80)3.456 ± 0.94183.350 ± 0.81723.240 ± 0.91433.135 ± 0.9906
FU Year 5 (n= 81, 79, 83, 74)3.391 ± 0.85553.305 ± 0.82063.201 ± 0.90992.932 ± 1.1391
SecondaryNumber of Participants Who Received Treatment With Antiviral, Immunomodulatory, Anti-inflammatory or Herbal/Botanical/Other Treatments for Chronic Hepatitis B

Participants who required additional treatments specifically to treat CHB, associated laboratory test abnormalities and associated symptoms in this long-term observation in the study were reported. Receipt of such treatment did not require participant withdrawal from further participation.

Time frame:
Up to 5-year FU period
Reported as:
Number · Participants
Number of Participants Who Received Treatment With Antiviral, Immunomodulatory, Anti-inflammatory or Herbal/Botanical/Other Treatments for Chronic Hepatitis B
ParticipantsGroup AGroup BGroup CGroup D
Nucleoside/nucleotide analogues49405136
Antiviral agents97189
Cytokines2899
Botanicals4649
Miscellaneous gastrointestinal agents5347
Miscellaneous drugs1121
Supplements2110
Pharmaceutic aids1110
Immunomodulators0200
Blood products0100
Chelating agents0100
Clotting factors and haemostatics0100
Prostaglandins0100
Vaccines, toxoids and serologic agents0100
Vitamins and minerals1000
SecondaryNumber of Participants With Clinically Significant Events Related to Chronic Hepatitis B (CHB)

Clinically significant events were defined as one or more of the following: Hepatocellular carcinoma, hepatic decompensation, CHB-related death, hepatic transplant, marked elevation of serum ALT of \>10 x upper limit of normal (ULN).

Time frame:
Up to 5-year FU period
Reported as:
Number · Participants
Number of Participants With Clinically Significant Events Related to Chronic Hepatitis B (CHB)
ParticipantsPEG-IFN 90mcg 24 WksPEG-IFN 180mcg 24 WksPEG-IFN 90mcg 48 WksPEG-IFN 180mcg 48 Wks
Elevated ALT >10 x ULN (Yes)3595
Elevated ALT >10 x ULN (No)89839790
Elevated ALT >10 x ULN (Missing)1100
Hepatic Decompensation (Yes)2011
Hepatic Decompensation (No)888710594
Hepatic Decompensation (Missing)3200
Hepatocellular Carcinoma (Yes)1030
Hepatocellular Carcinoma (No)20222221
Hepatocellular Carcinoma (No assessment performed)71668174
Hepatocellular Carcinoma (Missing)1100
Hepatic Transplant (No)928810695
Hepatic Transplant (Missing)1100
SecondaryNumber of Participants With Marked Laboratory Abnormalities

Marked abnormality of laboratory parameters is defined as the value which is outside the defined reference range of that respective parameter. Roche's following reference ranges for laboratory test parameters were used for the analysis: Hemoglobin (reference range: 110-200 grams/liter\[g/L\]), White blood cells (WBC) (3.0-18.0 \^10\^9/L), Platelets (100-550 \^10\^9/L), Neutrophils (1.50-9.25 \^10\^9/L), Prothrombin time (PT) Normal ratio (n.d.-2.00), Alkaline phosphatase (0-220 units/liter \[U/L\]), Alanine aminotransferase (0-110 U/L), Aspartate transaminase (0-80 U/L), Total bilirubin (0-34 micromole/liter \[umol/L\]), Gamma-glutamyl transpeptidase (GGT) (0-190 U/L), Blood urea nitrogen (BUN) (0.0-14.3 millimole/liter \[mmol/L\]), Creatinine (0-154 umol/L), Total Protein (55-87 g/L), Albumin (30.0-n.d. g/L), Potassium (2.9-5.8 mmol/L), Sodium (130-150 mmol/L), Calcium (2.00-2.90 mmol/L), Uric acid (0-600 umol/L). It includes marked abnormalities observed during Study WV19432 and FU study MV22430

Time frame:
Up to 5-year FU period
Reported as:
Number · Participants
Number of Participants With Marked Laboratory Abnormalities
ParticipantsPEG-IFN 90mcg 24 WksPEG-IFN 180mcg 24 WksPEG-IFN 90mcg 48 WksPEG-IFN 180mcg 48 Wks
Alanine transaminase (High)66677456
Aspartate transaminase (High)60606051
Albumin (Low)1210
Alkaline phosphatase (High)0211
BUN (High)0010
Calcium (High)0012
Calcium (Low)55157
Creatinine (High)0010
GGT (High)3577
Hemoglobin (Low)56113
Neutrophils (High)3222
Neutrophils (Low)53577977
PT normalized ratio (High)0100
Platelets (Low)14232841
Potassium (High)2142
Potassium (Low)1001
Prothrombin time (High)0110
Sodium (High)3010
Sodium (Low)0010
Total bilirubin (High)2483
Total protein (High)3156
Total Protein (Low)1010
Uric acid (High)1121
White blood cell (Low)27345265

Adverse events

Collected over 5-year FU period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PEG-IFN 90mcg 24 Wks—5/93 (5.4%)8/93 (8.6%)
PEG-IFN 180mcg 24 Wks—4/89 (4.5%)8/89 (9%)
PEG-IFN 90mcg 48 Wks—10/106 (9.4%)8/106 (7.5%)
PEG-IFN 180mcg 48 Wks—6/95 (6.3%)12/95 (12.6%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventPEG-IFN 90mcg 24 WksPEG-IFN 180mcg 24 WksPEG-IFN 90mcg 48 WksPEG-IFN 180mcg 48 Wks
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/930/893/1060/95
Hepatic function abnormalHepatobiliary disorders0/931/890/1060/95
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/931/891/1060/95
Pancreatitis acuteGastrointestinal disorders1/931/890/1060/95
Ovarian cystReproductive system and breast disorders0/931/890/1060/95
Dengue feverInfections and infestations1/930/890/1060/95
Hepatitis BInfections and infestations1/930/890/1060/95
Ectopic pregnancyPregnancy, puerperium and perinatal conditions1/930/890/1060/95
Alanine aminotransferase increasedInvestigations1/930/890/1061/95
Gastrointestinal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/930/890/1061/95
Most frequent other events
Most frequent other events
EventPEG-IFN 90mcg 24 WksPEG-IFN 180mcg 24 WksPEG-IFN 90mcg 48 WksPEG-IFN 180mcg 48 Wks
Upper respiratory tract infectionInfections and infestations5/936/894/1067/95
Alanine aminotransferase increasedInvestigations3/932/894/1065/95

Baseline characteristics

The Intent-to-Treat analysis population included all participants who had received at least one dose of study medication in study WV19432 and provided informed consent for study MV22430. Participants were analyzed according to the treatment groups to which they had been randomized.

Age, Continuous
Age, Continuous(years)PEG-IFN 90mcg 24 WksPEG-IFN 180mcg 24 WksPEG-IFN 90mcg 48 WksPEG-IFN 180mcg 48 WksTotal
Mean32.5 ± 9.7334.5 ± 10.5434.3 ± 10.8234.2 ± 10.7833.9 ± 10.49
Sex: Female, Male
Sex: Female, Male(Participants)PEG-IFN 90mcg 24 WksPEG-IFN 180mcg 24 WksPEG-IFN 90mcg 48 WksPEG-IFN 180mcg 48 WksTotal
Female34233335125
Male57647562258
08

Study locations

31 sites
  • Fitzroy, Victoria 3065, Australia
  • Salvador, BA 40210-341, Brazil
  • Campinas, SP 13083-888, Brazil
  • Ribeirao Preto, SP 14049-900, Brazil
  • Santo Andre, SP 09060-650, Brazil
  • Sao Paulo, SP 05403-000, Brazil
  • Beijing, 100050, China
  • Beijing, 100054, China
  • Changsha, 410008, China
  • Guangzhou, 510630, China
  • Shanghai, 200025, China
  • Shanghai, 201508, China
  • Hong Kong, 852, Hong Kong
  • Hong Kong, Hong Kong
  • Seoul, 110-744, Korea, Republic of
  • Seoul, 120-752, Korea, Republic of
  • Seoul, 138-736, Korea, Republic of
  • Auckland, 100, New Zealand
  • Hamilton, New Zealand
  • Samara, 443100, Russian Federation
  • St Petersburg, 190103, Russian Federation
  • Stavropol, 355017, Russian Federation
  • Singapore, 169608, Singapore
  • Kaohsiung, 807, Taiwan
  • Taipei, 100, Taiwan
  • Taoyuan, 333, Taiwan
  • Bangkok, 10400, Thailand
  • Bangkok, 10700, Thailand
  • Chiang Mai, 50202, Thailand
  • Khon Kaen, 40002, Thailand
  • Songkhla, 90112, Thailand
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2009
First posted
Jun 24, 2009
Start
Apr 2009
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Results first posted
Mar 9, 2016
Last update
Mar 9, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00927082
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 24, 2009
Start date
Apr 2009
Primary completion
Nov 2014
Completion
Nov 2014
Results posted
Mar 9, 2016
Last update
Mar 9, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2a

Start the discussion